Australia’s Vaxine Offers to Hold Clinical Trial for Potential Covid-19 Vaccine in the Philippines

Nov 2020

Australian biotechnology company, Vaxine Pty Ltd., has relayed its interest to the Philippines’ Department of Science and Technology (DOST) to conduct the second phase of clinical trials in the Philippines for its potential vaccine against Covid-19.

The Phase 2 trial will be conducted by DOST’s Vaccine Expert Panel (VEP) and is expected to begin by December 2020. It involves up to several hundred individuals and aims to define the optimal dose and safety profile of vaccine candidates. Vaxine is also keen to produce its vaccine locally once it has cleared of trials, been officially approved, and is ready to be administered to humans.

The company’s vaccine reportedly combines viral proteins with an adjuvant that stimulates the immune system, according to Covid-19 Vaccine Tracker by the New York Times. Vaxine had concluded its first phase of a trial in July 2020 with positive results after it conducted human trials on 40 participants.

Currently, there are about 7-8 companies, including global player, AstraZeneca, which have declared their interest in holding different stages of clinical trials in the country and are asking for process and requirements from the government.

(Source: Philippine Star)

About Us

Orissa International helps companies that want to develop a market entry strategy for Southeast Asia or implement their business expansion into the region. We have very strong domain knowledge of markets and industry sectors, and a business network of over 16,000 companies that includes distributors, resellers, system integrators and local manufacturers, that we have built through advising and guiding more than 5,000 companies with their market expansion into the ASEAN region over the last 25 years.

Orissa International is headquartered in Singapore, with additional offices in Malaysia, Indonesia, Thailand, Vietnam, and the Philippines.

Our Services